BCL2 and ovarian carcinoma: Analysis of ONCOMINE dataset revealed that paclitaxel-resistant ovarian cancer patients showed significantly higher expression of anti-apoptotic genes (Mcl-1, Bcl-2, Bcl-xL, and PARP) compared to paclitaxel-sensitive patients (P < 0.01; Figure 8(A)).